Updating results

114 results

Sort: Relevance | Date

Electrical stimulation to improve muscle strength in non-neurological chronic conditions: interventional procedure consultation

We are listening to your views on this interventional procedures guidance. Comments close 05 March 2020.

Interventional procedures guidance In consultation

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder: draft guidance

We are listening to your views on this medical technologies guidance. Comments close 13 March 2020.

In consultation

Faltering growth: quality standard consultation

We are listening to your views on this quality standard. Comments close 21 February 2020.

Quality standard In consultation

Suspected neurological conditions: quality standard consultation

We are listening to your views on this quality standard. Comments close 11 March 2020.

Quality standard In consultation

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 21 February 2020.

Technology appraisal guidance In consultation

Preterm labour and birth: surveillance consultation

We are listening to your views on this NICE guideline. Comments close 26 February 2020.

NICE guideline In consultation

Behaviour change: digital and mobile health interventions: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 06 March 2020.

NICE guideline In consultation

Acute coronary syndromes: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 27 March 2020.

NICE guideline In consultation

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 04 March 2020.

Technology appraisal guidance In consultation

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Proposed [GID-TA10612] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating severe eosinophilic asthma [ID3750]

Proposed [GID-TA10622] Expected publication date: TBC

Technology appraisal guidance Proposed

OTL-200 for treating metachromatic leukodystrophy [ID1666]

Proposed [GID-HST10028] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

Proposed [GID-TA10564] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Pelvic floor dysfunction

Proposed [GID-QS10129] Expected publication date: TBC

Quality standard Proposed

Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Technology appraisal guidance Proposed

Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

Proposed [GID-TA10555] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 22 July 2020

Technology appraisal guidance Proposed

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: 16 December 2020

Technology appraisal guidance Proposed

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Proposed [GID-TA10554] Expected publication date: TBC

Technology appraisal guidance Proposed

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Proposed [GID-TA10561] Expected publication date: TBC

Technology appraisal guidance Proposed

Ponesimod for treating relapsing multiple sclerosis [ID1393]

Proposed [GID-TA10556] Expected publication date: TBC

Technology appraisal guidance Proposed

Ofatumumab for treating relapsing multiple sclerosis [ID1677]

Proposed [GID-TA10557] Expected publication date: TBC

Technology appraisal guidance Proposed

Baloxavir marboxil for treating influenza [ID1537]

Proposed [GID-TA10559] Expected publication date: TBC

Technology appraisal guidance Proposed

Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

Proposed [GID-TA10560] Expected publication date: TBC

Technology appraisal guidance Proposed

Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

Proposed [GID-TA10562] Expected publication date: TBC

Technology appraisal guidance Proposed

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Proposed [GID-TA10563] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: 24 March 2021

Technology appraisal guidance Proposed

Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

Proposed [GID-TA10558] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Obeticholic acid for treating liver fibrosis in people with steatohepatitis [1645]

Proposed [GID-TA10606] Expected publication date: TBC

Technology appraisal guidance Proposed

Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

Proposed [GID-TA10609] Expected publication date: TBC

Technology appraisal guidance Proposed

Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]

Proposed [GID-TA10610] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Infant, children and young people's experience of health care

Proposed [GID-QS10102] Expected publication date: TBC

Quality standard Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Tinnitus

Proposed [GID-QS10091] Expected publication date: TBC

Quality standard Proposed

Heart valve disease in adults

Proposed [GID-QS10101] Expected publication date: TBC

Quality standard Proposed

Diverticular disease

Proposed [GID-QS10086] Expected publication date: TBC

Quality standard Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Gout

Proposed [GID-QS10100] Expected publication date: TBC

Quality standard Proposed

Housing: planning to improve health and wellbeing

Proposed [GID-QS10117] Expected publication date: TBC

Quality standard Proposed